Posizolid is an oxazolidinone antibiotic under investigation by AstraZeneca for the treatment of bacterial infections. At a concentration of 2 mg/L it inhibited 98% of all Gram-positive bacteria tested in vitro.[1]
Clinical data | |
---|---|
Other names | AZD2563 |
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.234.485 |
Chemical and physical data | |
Formula | C21H21F2N3O7 |
Molar mass | 465.410 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
References
edit- ^ Wookey A, Turner PJ, Greenhalgh JM, Eastwood M, Clarke J, Sefton C (March 2004). "AZD2563, a novel oxazolidinone: definition of antibacterial spectrum, assessment of bactericidal potential and the impact of miscellaneous factors on activity in vitro". Clinical Microbiology and Infection. 10 (3): 247–54. doi:10.1111/j.1198-743X.2004.00770.x. PMID 15008947.